Genitourinary Malignancies Program
Description of the Program
The Genitourinary Malignancies Program consists of scientists and physicians who are committed to research that has the potential to impact the outcomes of patients with prostate, bladder and kidney cancers. Program members have a particular interest in biomarker documentation for risk stratification and molecular target identification. The program leaders are Drs. Cote, Lee, and Pollack, who all have a major research focus on GU malignancies.
Goals of the Program
- Discover and understand the mechanisms of relevant markers for patients who are candidates for active surveillance and those with primary local-regional, recurrent and metastatic malignancies.
- Develop model systems to evaluate mechanisms of progression and response
- Considering the mechanisms identified, design informed chemoprevention and therapeutic strategies that enhance or replace standard management with surgery, radiotherapy, or systemic therapy.
The following themes are being developed:
Determinants of patient outcome in multi-ethnic populations; addressing health care disparities
- Sub-theme: Tissue biomarkers/gene expression signatures
- Sub-theme: Blood markers (e.g, CTCs)
- Sub-theme: Multiparametric imaging markers
Correct diagnosis and correct treatment of GU malignancies; addressing health care disparities
- Sub-theme: Surveillance & biomarker driven chemoprevention
- Sub-theme: Targeted therapy & Immunomodulation
- Sub-theme: Cell culture and response
Cancer cell adaptation to the tumor microenvironment and [health disparities]
- Sub-theme: Epigenetic signature and Preclinical modelling of hypoxia signaling
- Sub-theme: microRNA and metastasis
- Sub-theme: Androgen receptor signaling axis